FDA approves ZANVASTRO for Alexander disease, expanding access
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. Approval was based on clinical data showing motor function benefit and favorable safety.
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults.
Approval was based on robust clinical data showing significant motor function benefit and favorable safety.
Launch efforts focus on rapid patient access, payer coverage…